Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (61-70 of 471) with videos related to

Pageof 48
Sort By:
Cancer|August 17, 2005
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi, David Dingli, Chin-Yang Li, et al.
Hematology (Amsterdam, Netherlands)|February 9, 2026
Switching patients with PNH from pegcetacoplan to iptacopan: a case seriesMark Orland, Carmelo Gurnari, Srinivasa Sanikommu, et al.
Haematologica|July 2, 2013
Schnitzler syndrome: an under-diagnosed clinical entityTania Jain, Chetan P Offord, Robert A Kyle, et al.
Journal of Comparative Effectiveness Research|September 1, 2023
The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USAJesse Fishman, Koo Wilson, Aleksandra Drzewiecka, et al.
Drugs in R&D|May 10, 2024
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with PegcetacoplanBrian P Mulherin, Michael Yeh, Mohammed Al-Adhami, et al.
BMC Cancer|May 1, 2019
How many samples are needed to infer truly clonal mutations from heterogenous tumours?Luka Opasic, Da Zhou, Benjamin Werner, et al.
Plos Computational Biology|June 19, 2018
Evolutionary dynamics of paroxysmal nocturnal hemoglobinuriaNathaniel Mon Père, Tom Lenaerts, Jorge M Pacheco, et al.
Plos Computational Biology|October 21, 2016
Optimized Treatment Schedules for Chronic Myeloid LeukemiaQie He, Junfeng Zhu, David Dingli, et al.
Medicine|July 17, 2007
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemiaKeith W Pratz, David Dingli, Thomas C Smyrk, et al.
Journal of Theoretical Biology|March 5, 2008
Modeling of cancer virotherapy with recombinant measles virusesZeljko Bajzer, Thomas Carr, Kresimir Josić, et al.
Pageof 48

Showing results (61-70 of 471) with videos related to

Sort By:
Pageof 48
Cancer|August 17, 2005
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi, David Dingli, Chin-Yang Li, et al.
Hematology (Amsterdam, Netherlands)|February 9, 2026
Switching patients with PNH from pegcetacoplan to iptacopan: a case seriesMark Orland, Carmelo Gurnari, Srinivasa Sanikommu, et al.
Haematologica|July 2, 2013
Schnitzler syndrome: an under-diagnosed clinical entityTania Jain, Chetan P Offord, Robert A Kyle, et al.
Journal of Comparative Effectiveness Research|September 1, 2023
The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USAJesse Fishman, Koo Wilson, Aleksandra Drzewiecka, et al.
Drugs in R&D|May 10, 2024
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with PegcetacoplanBrian P Mulherin, Michael Yeh, Mohammed Al-Adhami, et al.
BMC Cancer|May 1, 2019
How many samples are needed to infer truly clonal mutations from heterogenous tumours?Luka Opasic, Da Zhou, Benjamin Werner, et al.
Plos Computational Biology|June 19, 2018
Evolutionary dynamics of paroxysmal nocturnal hemoglobinuriaNathaniel Mon Père, Tom Lenaerts, Jorge M Pacheco, et al.
Plos Computational Biology|October 21, 2016
Optimized Treatment Schedules for Chronic Myeloid LeukemiaQie He, Junfeng Zhu, David Dingli, et al.
Medicine|July 17, 2007
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemiaKeith W Pratz, David Dingli, Thomas C Smyrk, et al.
Journal of Theoretical Biology|March 5, 2008
Modeling of cancer virotherapy with recombinant measles virusesZeljko Bajzer, Thomas Carr, Kresimir Josić, et al.
Pageof 48